Skyscape Web Viewer : Radiation Oncology Question Review : Main Index

View All
Liver tumors in children adjuvant radiation, doses for benign vs malignant hemangioblastoma hepatoblastomas hepatocellular carcinoma histopathology neoadjuvant radiation, doses for staging system typical presentation
lobular carcinoma in situ (LCIS) Answer 3.50 Answer 3.51 Answer 3.52 Question 3.50 Question 3.51 Question 3.52
Locally advanced breast cancer characteristics constraints danish PMRT trials dermal lymphatic invasion diagnosis eligibility criteria locoregional recurrence lymphedema neoadjuvant chemotherapy postmastectomy radiation therapy (PMRT) trial treatment WBI and RNI
Locally advanced squamous cell cancer Question 1.1 Question 1.3
LPHL
Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis
lymphocyte-predominant Hodgkin lymphoma (LPHL) Answer 8.46 Answer 8.47 Question 8.46 Question 8.47
Medulloblastomas CCG 921 high-risk medulloblastoma trial chang staging system craniospinal irradiation (CSI) genetic syndromes associated with incidence rate management prognostic factors risk factors
Melanoma grade 3 subcutaneous tissue fibrosis hypofractionation MLST II trial resection of sentinel lymph node biopsy (SLNB)
Meningiomas dose-response relationship in fractionated radiation radiosurgery resection grades risk groups stereotactic radiosurgery
Merkel cell carcinoma adjuvant chemotherapy adjuvant radiotherapy margin of resection radiotherapy dose sentinel LN biopsy (SLNB)
Mesothelioma adjuvant IMRT cause factors common contralateral lung V20 therapy first-line chemotherapy histologic subtypes IMPRINT trial prognostic factors treatment paradigm
Methylphenidate Answer 2.106 Question 2.106
Multiple myeloma Answer 8.49 bone marrow biopsy Question 8.49 radiation therapy, dose/fractionation for solitary extramedullary plasmacytoma and solitary plasmacytoma of bone
Nasopharynx clinical presentations dose constraints endoscopic examination of induction or adjuvant chemotherapy locally advanced NPC lymphadenopathy nasopharyngeal lesions patients percentage radiation related factor subtypes and risk factor TNM staging treatment
Neuroblastoma EFS rate features/symptoms median age of diagnosis radiotherapy staging
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) Answer 10.28 Question 10.28
non-Hodgkin lymphoma
Non-melanomatous skin cancer adjuvant RT BWH staging system dosing regimens higher dose/fraction immunosuppressed patients LN involvement radiation delivery techniques
Non-small cell lung cancer-early stage
Non-small cell lung cancer-locally advanced
Optic gliomas, risk of primary tumors in Answer 2.99 Question 2.99
Oral cavity "t" staging for lip independent prognostic factor subsites of T4 lesion treatment approach
Oropharyngeal cancer common assays h&n subsite HPV+ and HPV- disease p16+ oropharynx prognostic significance risk of contralateral nodal involvement risk of ipsilateral and bilateral nodal disease risk of microscopic involvement transoral robotic surgery (TORS)
Osteosarcoma affected population chemotherapy common sites incidence rate radiation dose survival rate for nonmetastatic and metastatic T-n-m staging
Pancreatic cancer
Paranasal sinus anticipated 5-yr LRC and OS effect of orbital involvement neuroendocrine differentiation Ohngren's line and Vidian canal staging system for esthesioneuroblastoma subclinical nodal involvement
PCI
Pediatric gliomas genetic syndrome high-grade histologic subtypes second malignancy, risk of treatment approach
Pediatric leukemia cranial irradiation pediatric ALL and AML prognostic features of ALL prognostic features of AML